Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
Follow ORGS
Orgenesis Inc. (ORGS) EV/Sales
As of 15 October 2026, Orgenesis Inc. (ORGS) trades at a EV/Sales of 15.7×. Over the past ten years it has ranged from −6.1× (April 2020) to 88.5× (March 2024); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 23.2× | (65.02%) |
| FY2023 | 66.2× | 3,824.83% |
| FY2022 | 1.7× | (19.86%) |
| FY2021 | 2.1× | (73.92%) |
| FY2020 | 8.1× | (63.63%) |
| FY2019 | 22.2× | 772.92% |
| FY2018 | 2.5× | (47.18%) |
| FY2018 | 4.8× | (29.38%) |
| FY2017 | 6.8× | 15.46% |
| FY2017 | 5.9× | (20.87%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 23.2× | (40.60%) |
| Sep 2024 | 39.0× | (26.78%) |
| Jun 2024 | 53.2× | (37.04%) |
| Mar 2024 | 84.5× | 27.73% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −352× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −40.1× |
| CANF Can-Fite Biopharma Ltd compare | −8.6× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| BGMS Bio Green Med Solution, Inc. compare | 0.7× |
| IMNN Imunon, Inc. compare | 8.0× |
| ORGS Orgenesis Inc. | 15.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)